Clinical trials: Subcutaneous Fat, open to volunteers
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07526974
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- NCT07608757
- Testing
- CBL-514 Injection
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
- Trial name
- NCT07608770
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- Australia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
- Trial name
- SUPREME-01 (NCT07140939)
- Testing
- CBL-514 Injection, 0.9% Sodium Chloride
- Where
- 13 sites in United States, Canada
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Subcutaneous Fat
A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
- Trial name
- NCT07733947
- Testing
- CBL-514 Injection, 0.9 % sodium chloride
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Morbid, Brown Fat, Metabolic Disease
- Trial name
- NCT03875625
- Testing
- Bariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong